Background The incidence and severity of herpes zoster and postherpetic neuralgia
increase with age in association with a progressive decline in cell-mediated immunity to …

Background A double-blind, placebo-controlled trial that involved 38,546 subjects⩾ 60 years
old demonstrated efficacy of a high-potency live-attenuated Oka/Merck varicella-zoster virus …

The safety and immunogenecity of a booster dose of live attenuated varicella-zoster virus
(VZV) vaccine was evaluated in 196 healthy subjects,⩾ 60 years old, who had already …

Background The objectives of this study were to evaluate the association between varicella-
zoster virus (VZV)–specific humoral and cell-mediated immunity (CMI) to herpes zoster (HZ) …

We report an association between X-linked immunodeficiency with hyper-IgM (XHIM) and
carcinomas affecting the liver, pancreas, biliary tree, and associated neuroectodermal …

Immunodeficiency with hyper-IgM was described by Israel-Asselain et al. in 1960 [1] and
Rosen et al. in 1962 [2]. It is characterized by recurrent infections, very low or undetectable …

Aortic allograft fibrocalcification and valvular insufficiency have been observed in patients
less than 3 years of age at initial replacement of the left ventricular outflow tract. From June …

Background. Varicella-zoster virus (VZV)-specific cell-mediated immunity is important for
protection against VZV disease. We studied the relationship between VZV cell-mediated …

The Oka strain live attenuated varicella-zoster virus (VZV) vaccine was administered
subcutaneously to 202 VZV-immune individuals who were 55 to> 87 years old. The dose …

In six infants, from two families, the umbilical cords were still attached at 3 weeks of age. Five
of these developed severe local and disseminated bacterial infections from which four died …